Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis has entered a multi-billion dollar agreement to utilize Alteogen's subcutaneous drug delivery technology.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent coverage from outlets including Reuters, Fierce Biotech, BioWorld News, and Seeking Alpha details a major business transaction within the pharmaceutical sector. Novartis has signed an option and license agreement valued at up to $3.2 billion or approximately 4.4 trillion for Alteogen's drug delivery technology. According to reporting by Gurufocus, Finimize, and FirstWord Pharma, this multi-billion dollar pact targets faster drug delivery through subcutaneous injection formulations. The agreement involves Alteogen's specific technology, identified as ALT-B4, which supports subcutaneous drug ambitions. Additional reports from Pharmaceutical Executive, PharmTech.com, and the Seoul Economic Daily emphasize the broader formulation implications of this transaction.
Coverage notes that Alteogen's value is set for potential rerating as its subcutaneous platform extends from antibody-drug conjugates (ADCs) to antibody-oligonucleotide conjugates (AOCs). The Seoul Economic Daily and other specialized publications examine what this enzyme licensing deal means for modern drug formulation and how pharmaceutical companies are approaching subcutaneous delivery methods. Financial and market analysts have begun responding to the agreement across several platforms. TipRanks and Investing.com UK report that H.C. Wainwright has reiterated its stock rating for Halozyme while specifically viewing the Novartis and Alteogen pact as negative for Halozyme due to emerging deal momentum.
Meanwhile, broad financial coverage from Finimize and Gurufocus notes that healthcare stocks generally rose following the announcement of the cut deal between Novartis and Alteogen. Coverage does not yet specify the exact timeline for clinical development milestones or the specific product candidates Novartis plans to advance using the ALT-B4 technology. Observers and market participants will monitor further disclosures from both companies regarding the execution of the option and license agreement. Financial analysts will also track subsequent stock rating adjustments and sector-wide reactions as the multi-billion dollar partnership progresses through its initial stages.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 71d ago.
Quick answers
What is the financial value of the deal between Novartis and Alteogen?
According to coverage from Reuters, Seeking Alpha, and Fierce Biotech, the deal is valued at up to $3.2 billion, which is also cited in regional coverage as up to 4.4 trillion.
Which specific technology is Novartis licensing from Alteogen?
Coverage from BioWorld News and other outlets states that Novartis is utilizing Alteogen's ALT-B4 technology for subcutaneous drug delivery and subcutaneous injection formulation.
How has the market or analyst community reacted to the pact?
Reporting from TipRanks and Investing.com UK indicates that H.C. Wainwright reiterated its Halozyme stock rating while viewing the Novartis-Alteogen pact as negative for Halozyme, while general healthcare stocks rose according to Finimize and Gurufocus.
Coverage (13)
- H.C. Wainwright reiterates Halozyme stock rating on deal momentum By Investing.com Investing.com UK · 74d ago
- Novartis Rises as $3.22 Billion Deal Targets Faster Drug Deliver gurufocus.com · 74d ago
- Novartis chooses Alteogen tech for subcutaneous drug ambitions firstwordpharma.com · 74d ago
- Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq Pharmaceutical Executive · 74d ago
- Alteogen Value Set for Rerating as SC Platform Extends From ADCs to AOCs Seoul Economic Daily · 74d ago
- Novartis taps Alteogen’s ALT-B4 for SC drug delivery in $3B deal BioWorld News · 74d ago
- Healthcare Stocks Rose As Novartis Cut A Deal With Alteogen Finimize · 74d ago
- Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B Seeking Alpha · 74d ago
- Alteogen has signed a subcutaneous injection (SC) formulation technology contract worth up to 4.4 tr.. 매일경제 · 74d ago
- H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme TipRanks · 74d ago
- What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation PharmTech.com · 74d ago
- Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology Reuters · 74d ago
- Novartis inks $3.2B subcutaneous delivery deal with Alteogen Fierce Biotech · 74d ago
Topics
Related trends
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's experimental drug sefaxersen meets its primary endpoint in a late-stage study for the autoimmune disease IgAN.
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.